TDC
XENT

Thompson Davis & Co’s Intersect ENT, Inc XENT Stock Holding History

Thompson Davis & Co’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-374
Closed -$5K – 1207
2016
Q2 		$5K Hold
374
– – 0.01% 799
2016
Q1 		$7K Hold
374
– – 0.01% 725
2015
Q4 		$8K Sell
374
-125
-25% -$2.47K 0.01% 731
2015
Q3 		$12K Buy
499
+249
+100% +$6.87K 0.02% 616
2015
Q2 		$7K Hold
250
– – 0.01% 829
2015
Q1 		$6K Hold
250
– – 0.01% 872
2014
Q4 		$5K Buy
250
+125
+100% +$2.25K 0.01% 951
2014
Q3 		$2K Buy
+125
New +$1.88K ﹤0.01% 1072

Other funds holding XENT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Thompson Davis & Co's XENT Position: Q3 2016 in Review

Thompson Davis & Co sold out of Intersect ENT, Inc (XENT) in Q3 2016, closing a stake of 374 shares — an estimated $5K sold.

Thompson Davis & Co first reported a position in XENT in Q3 2014 and held it in 8 quarters. The position peaked at $12K in Q3 2015. 98 funds tracked by Wall St. Rank hold XENT as of Q3 2016.

  • Thompson Davis & Co reported no remaining Intersect ENT, Inc position as of Q3 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 374 Intersect ENT, Inc shares in Q3 2016, an estimated $5K.
  • Thompson Davis & Co first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 8 quarters.
  • Thompson Davis & Co's Intersect ENT, Inc position peaked at $12K in Q3 2015.
  • 98 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q3 2016.

Based on Thompson Davis & Co's 13F filing for Q3 2016, filed 8 Nov 2016.